Stroke: Covidien battles “failed” clot-removing device study

Covidien's Solitaire FR revascularization device

Medical device maker Covidien (NYSE:COV) touted 2-year study results demonstrating the safety and efficacy of its Solitaire FR revascularization system, combating another recently published study that questioned whether devices like Solitaire in provide long-term benefits to stroke patients.

The Solitaire FR device helps restore blood flow to the brain by removing blood clots that hinder circulation. Stroke patients with blood clots can suffer brain damage or even death if the brain is deprived of proper blood flow for too long.

Covidien’s study demonstrated that the Solitaire FR was successful in reopening blocked blood vessels with low rates of adverse events or patient deaths, but a government-funded study questioned whether manual blood clot removal was ultimately better for patients than treatment with drugs alone.

The current standard of care for stoke patients involves treatment with clot-busting drugs that help dissolve blood clots over time. In a study funded by the National Institutes of Health and the National Institute of Neurological Disorders & Stroke found that patients who underwent manual clot removal, or thrombectomy, didn’t see much improvement in overall outcomes when compared with patients who only received a clot-busting drug, IV t-PA, an intravenous tissue plasminogen activator.

Manual thrombectomy was 40% more likely to get rid of blood clots, according to the NIH/NINDS trial, the only study of its kind to directly balance the risks and benefits of adding medical device intervention to acute stroke treatment. However, the reopening of the blocked artery didn’t improve patients’ disability due to stroke when compared with patients who only received drugs to dissolve the clots, according to the report.

"This is the largest trial of an intra-arterial intervention for acute ischemic stroke, and is important because it shows that the addition of devices to treat clots within the brain artery was no more effective than treatment with IV t-PA alone," NINDS deputy director Dr. Walter Koroshetz said in prepared remarks. "Such devices are already widely used in clinical practice based on dramatic improvements seen in individuals, but without evidence supporting their overall clinical effectiveness in a large group."

The researchers ceded that their study, unlike pilot more successful studies that came before, featured an important difference in patient treatment – a delay. Patients on average waited about 32 minutes longer between initial drug therapy and manual clot removal than patients in previous trials.

"We probably did not open the arteries quickly enough," lead researcher Dr. Joseph Broderick said in prepared remarks. The report noted, however, that real-world patient treatment is rife with delays.

"Most patients do not have immediate access to the level of care required to perform intra-arterial procedures," according to a press release. "Instead, they are often treated with IV t-PA at a local hospital then transferred to another hospital, all of which further delays the time to treatment."

Covidien researchers were quick to respond to the study results with results of their own from a 2-year follow-up of patients who received treatment with the Solitaire FR revascularization system in the Solitaire FR Thrombectomy for Acute Revascularization (STAR) study.

More than 84% of the 190 patients with complete data sets achieved the highest levels of recanalization, a measure of the openness of the blood vessel. Nearly 60% of patients reported functional independence 90 days after treatment, indicating little to no disability, according to the Covidien press release.

The company brought on an independent Core Lab to assess patient outcomes and and independent Clinical Events Committee to assess adverse events. The committee reported a 6.9% mortality rate and a 1.5% symptomatic intracranial hemorrhage rate.

"In the wake of the failed IMS III Study, a NINDS-funded randomized controlled trial, there will be some physicians who will question the benefit of mechanical thrombectomy," principal STAR investigator Dr. Vitor Mendes Pereira said in prepared remarks. "The results of the STAR prospective, multi-center clinical study demonstrate that mechanical thrombectomy is both safe and effective for the treatment of acute ischemic stroke when treating the right patients, in comprehensive stroke centers, with the Solitaire FR device."

RSS From Medical Design & Outsourcing

  • 3-phase current transducer from PEM delivers all-in-one convenience
    The new RCTrms 3-ph current transducer from Power Electronic Measurements (PEM) delivers a convenient, safe and accurate solution for measuring current in three phases. It features a thin, clip-around, flexible sensor coil and provides accurate true rms measurement with 4-20 mA or 0-5 V output, enabling simple installation with PLC’s, SCADA systems or automation equipment. […]
  • Safety alert: Recall on two IV solutions from Baxter
    Baxter International announced it is voluntarily recalling two lots of intravenous (IV) solutions to the hospital and user level due to the potential presence of particulate matter. The particulate matter in each case was determined to be an insect and was identified as a result of a customer complaint. The matter was identified prior to […]
  • TSO3 begins shipment of STERIZONE VP4 Sterilizers to U.S.
    TSO3, a developer in sterilization technology for medical devices in healthcare settings, announced that the company has received purchase orders for multiple devices from the U.S. The orders are the result of the collaborative relationship between Getinge Infection Control, its sales and service provider, and TSO3. “Finally,” said R.M. Rumble, president and CEO of TSO3. “Our Vision is […]
  • Turkish medical company is seeking reseller and OEM partners in the U.S.
    UZUMCU Medical Equipment, one of Turkey’s first and largest manufacturers of medical devices, is seeking reseller and OEM partners in the U.S. The company has an array of FDA-certified OR tables, surgical lights, surgical suction units, electro devices and other medical equipment. “We want to bring our experience with distributors throughout Europe and the Middle […]
  • QImaging introduces new CCD cameras for microscopy with modern software to streamline image capture
    QImaging, a manufacturer of scientific cameras for life science and OEM applications, introduces a new series of Retiga CCD cameras, accompanied by QImaging’s new acquisition software to deliver high-performance tools for microscopy and imaging to researchers at an affordable price. The new QImaging Retiga R1, Retiga R3 and Retiga R6 cameras offer valuable technical features […]
  • Sigma-Aldrich announces a new certification to aid IVD customers
    Sigma-Aldrich, a life science and high technology company, announced the company has received ISO 13485 certification for expanded quality assurance capabilities at its Dekalb and Barton facilities located in St. Louis. The certification extends Sigma-Aldrich’s ability to manufacture and offer critical raw materials, such as enzymes, proteins and antibodies used in diagnostic assays, and supplies in vitro […]
  • Prescribing the right power supply: Important considerations for using batteries to power medical devices
    Sol Jacobs, VP and General Manager, Tadiran Batteries Medical technology is advancing rapidly, requiring increasingly sophisticated power management solutions, especially when then the device needs to be self-powered. Battery-powered medical devices encompass a wide range of applications, including surgical drills, power tools, automatic external defibrillators (AEDs), infusion pumps, bone growth stimulators and other wearable devices, […]
  • Qosina announces the launch of its e-commerce website
    Qosina is pleased to announce the launch of its e-commerce website, making it easier to purchase thousands of medical device components from stock inventory. Visitors coming to the new Qosina.com will discover a new look and feel and improvements with every click including: · Easy navigation: A new category structure that mirrors the print catalog […]
  • Athermal laser machining for medical implants is the topic of Norman Noble’s latest whitepaper
    Thermal lasers have achieved extraordinary results in microprecision manufacturing of medical implants and devices the past 20 years. Devices we take for granted today, such as vascular stents, could not be produced without the technology; however, there are still significant limitations on what medical implant and device manufactures can produce using thermal lasers. One major issue […]
  • Sealevel announces the SeaISO family of USB isolators
    Sealevel announces the SeaISO family of USB isolators with 4 kV of medical-grade optical isolation between the host computer and connected USB equipment. SeaISO USB isolators are UL Recognized, in accordance with EN60601-1 3rd Edition, and protect both the power and data lines of connected USB devices from harmful ground loops, damaging transients and surges […]
  • The 21st Century Cures Discussion document recently released to the public
    It has been reported that among the 10,000 known diseases, 7,000 of which are considered rare, there are treatments for only 500. According to Dr. Francis Collins, Director of the National Institutes of Health (NIH), it now takes “around 14 years and $2 billion or more” to develop a new drug and “more than 95% […]

Leave a Reply